ASND · Ascendis Pharma A/S · Webcasts, Transcripts & Audio
$271.19
-0.54 (-0.20%)
At close · Nov 17
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$17.79B
Shares
65.60M
Volume · Nov 17
586.93K
Avg daily vol (3M)
735.38K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Ascendis Pharma A/S Webcasts
Earnings calls, investor updates, investor days and conferences for Ascendis Pharma A/S (ASND), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-12
Ascendis Pharma A/S (ASND) Q3 2026 Earnings Call
Revenue
369.66M EUR
▲ 73% YoY Diluted EPS
1.08
Gross margin
92.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-15
Ascendis Pharma A/S (ASND) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-13
Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call Transcript
Confident tone
Global commercialization infrastructure
TransCon Combination Trial (COACH) results
UVA Well (TransCon hGH) launch and competition
Revenue
339.29M EUR
▲ 114.7% YoY Diluted EPS
2.83
Gross margin
91.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript
Confident tone
YORVIPATH commercial performance
YUVIWEL launch (TransCon CNP)
Competition in hypoparathyroidism
Revenue
246.60M EUR
▲ 144.3% YoY Diluted EPS
9.75
Gross margin
92.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-11
Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript
Confident tone
Yorvipath commercial launch and growth
TransCon CNP and combination therapy in achondroplasia
Skytrofa / TransCon Growth Hormone
Revenue
247.50M EUR*
▲ 42.3% YoY Gross margin
90.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript
Confident tone
Eurvipath commercial launch
Growth disorders portfolio
Financial performance and profitability
Revenue
213.63M EUR
▲ 269.4% YoY Diluted EPS
-1.00
Gross margin
89.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Ascendis Pharma A/S (ASND) Q2 2025 Earnings Call Transcript
Confident tone
YORVIPATH commercial launch
TransCon CNP in achondroplasia
Combination therapy / COACH trial
Revenue
158.04M EUR
▲ 339% YoY Diluted EPS
-0.82
Gross margin
80.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript
Confident tone
YORVIPATH U.S. launch performance
Path to cash flow positive and financial outlook
SKYTROFA franchise and label expansion
Revenue
100.95M EUR
▲ 5.3% YoY Diluted EPS
-1.58
Gross margin
82.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Date not confirmed
Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript
Confident tone
YORVIPATH U.S. launch and hypoparathyroidism opportunity
SKYTROFA growth hormone franchise
TransCon CNP and achondroplasia
Revenue
173.92M EUR*
▲ 26.3% YoY Gross margin
91.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Date not confirmed
Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript
Confident tone
SKYTROFA growth and U.S. commercial performance
YORVIPATH U.S. launch readiness
Full-year 2024 revenue guidance
Revenue
57.83M EUR
▲ 20.4% YoY Diluted EPS
-1.72
Gross margin
80.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Date not confirmed
Ascendis Pharma A/S (ASND) Q2 2024 Earnings Call Transcript
Confident tone
SKYTROFA Market Access Reset
YORVIPATH US Launch
YORVIPATH Europe Commercialization
Revenue
36.00M EUR
▼ 24% YoY Diluted EPS
-1.91
Gross margin
68.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Date not confirmed
Ascendis Pharma A/S (ASND) Q1 2024 Earnings Call Transcript
Confident tone
SKYTROFA U.S. commercial performance
TransCon CNP achondroplasia program
TransCon PTH U.S. PDUFA and prelaunch
Revenue
95.89M EUR
▲ 185.5% YoY Diluted EPS
-2.30
Gross margin
92.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Date not confirmed
Ascendis Pharma A/S (ASND) Q4 2023 Earnings Call Transcript
Revenue
137.70M EUR*
▲ 501.4% YoY Gross margin
85.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Date not confirmed
Ascendis Pharma A/S (ASND) Q3 2023 Earnings Call Transcript
Revenue
48.03M EUR
▲ 214.2% YoY Diluted EPS
-2.88
Gross margin
84.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Date not confirmed
Ascendis Pharma A/S (ASND) Q2 2023 Earnings Call Transcript
Revenue
47.39M EUR
▲ 669.4% YoY Diluted EPS
-2.16
Gross margin
72.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Date not confirmed
Ascendis Pharma A/S (ASND) Q1 2023 Earnings Call Transcript
Revenue
33.59M EUR
▲ 391.9% YoY Diluted EPS
-1.98
Gross margin
86.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Date not confirmed
Ascendis Pharma A/S (ASND) Q4 2022 Earnings Call Transcript
Revenue
22.90M EUR*
▲ 367.6% YoY Gross margin
77.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Date not confirmed
Ascendis Pharma A/S (ASND) Q3 2022 Earnings Call Transcript
Revenue
15.29M EUR
▲ 1273.8% YoY Diluted EPS
-3.03
Gross margin
88.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Date not confirmed
Ascendis Pharma A/S (ASND) Q2 2022 Earnings Call Transcript
Revenue
6.16M EUR
▲ 502.7% YoY Diluted EPS
-1.46
Gross margin
82.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Date not confirmed
Ascendis Pharma A/S (ASND) Q1 2022 Earnings Call Transcript
Revenue
6.83M EUR
▲ 815.3% YoY Gross margin
37.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Date not confirmed
Ascendis Pharma A/S (ASND) Q4 2021 Earnings Call Transcript
Revenue
4.90M EUR*
▲ 815.3% YoY Gross margin
28.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-09-30
Date not confirmed
Ascendis Pharma A/S (ASND) Q3 2021 Earnings Call Transcript
Revenue
1.11M EUR
▼ 59.6% YoY Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Date not confirmed
Ascendis Pharma A/S (ASND) Q2 2021 Earnings Call Transcript
Revenue
1.02M EUR
▼ 28.8% YoY Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Date not confirmed
Ascendis Pharma A/S (ASND) Q1 2021 Earnings Call Transcript
Revenue
746,000 EUR
▼ 66.5% YoY Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Date not confirmed
Ascendis Pharma A/S (ASND) Q4 2020 Earnings Call Transcript
Revenue
535,000 EUR*
▼ 78.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Date not confirmed
Ascendis Pharma A/S (ASND) Q3 2020 Earnings Call Transcript
Revenue
2.76M EUR
▲ 22.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Date not confirmed
Ascendis Pharma A/S (ASND) Q2 2020 Earnings Call Transcript
Revenue
1.44M EUR
▼ 55.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
Date not confirmed
Ascendis Pharma A/S (ASND) Q1 2020 Earnings Call Transcript
Revenue
2.23M EUR
▼ 58.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–28 of 28 webcasts
Key facts
CIK
1612042
CUSIP
K08588103
13F (30d)
363 filings
333 filers
Visit website
Investor relations